CLINICAL ROLE -
The Illusion of Relief: Rethinking Our Cold Medicine Cabinet
Recent FDA findings highlight that a major ingredient in popular cold fighters, phenylephrine, may not offer genuine relief.
Read More
How a Rebirth Toward Preventing Inflammation Will Positively Impact Age-Related Diseases, Extend Longevity
Diagnostic technologies are advancing quickly, which may lead to therapeutics for age-related diseases to safely reduce chronic low-grade inflammation generated by the immune system.
Connecting the Dots: Alcohol Hangover, Inflammation, and Aging
The FDA considers alcohol hangover as a disease, requiring treatments to be registered as drugs.
The Balancing Act of Vaccines
As pharmacists, it’s important to understand and embrace the science and the tools that COVID-19 has brought.
Addressing the Mystery of Long Hauler COVID: The Time is Now
As we learn more about inflammatory syndromes, we may get better at using laboratory tests to identify and isolate the actual cellular and chemical processes that drive them.
Alcohol Hangover is Classified as a Disease: What Does That Mean For Treating Hangovers Therapeutically?
New research may offer pharmacists a better means of helping customers manage the symptoms of an alcohol hangover.
Solutions in the Search for Lower-Cost, Smart Pharmaceuticals
Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.
The Case for Repurposing Established Drugs in Novel Combination Therapies
Is big pharma overlooking the Goldilocks solutions right under our nose?
The Fight to Treat COVID-19: Sorting Through Therapeutics From Antivirals to Anti-inflammatories
Millions of people are still getting COVID-19, so the need for additional tools to fight the virus remains strong.
The Real Reason Why COVID-19 is Exceedingly Difficult To Manage
Ending the COVID-19 pandemic requires an understanding of how to manage the inflammatory dysfunction that the virus causes.
